Profile data is unavailable for this security.
About the company
Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development, manufacture and sale of over-the-counter drugs and vaccines, the provision of administrative services such as human resources and accounting services, real estate leasing and insurance agency business.
- Revenue in USD (TTM)11.31bn
- Net income in USD1.61bn
- Incorporated2005
- Employees18.73k
- LocationDaiichi Sankyo Co LtdDaiichi Sankyo Bldg. A/B Kan3-5-1, Nihombashi Hon-choCHUO-KU 103-8426JapanJPN
- Phone+81 362251111
- Websitehttps://www.daiichisankyo.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. | 2.09bn | -332.26m | 32.09bn | 2.10k | -- | 990.74 | -- | 15.32 | -2.62 | -2.62 | 16.52 | 0.2511 | 0.5208 | 3.57 | 8.41 | 997,521.40 | -8.26 | -26.56 | -11.31 | -32.77 | 85.37 | 83.66 | -15.86 | -94.26 | 2.69 | -1.36 | 0.9694 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
| Daiichi Sankyo Co Ltd - ADR | 11.31bn | 1.61bn | 56.68bn | 18.73k | 34.33 | 5.25 | 27.96 | 5.01 | 0.8419 | 0.8419 | 5.91 | 5.51 | 0.5913 | 1.01 | 3.73 | 604,027.30 | 8.43 | -- | 10.51 | -- | 76.11 | -- | 14.26 | -- | 2.24 | -- | 0.0589 | -- | 25.28 | -- | 85.90 | -- | -- | -- |
| Zoetis Inc | 9.15bn | 2.43bn | 79.26bn | 14.10k | 33.03 | 15.16 | 26.98 | 8.66 | 5.32 | 5.32 | 20.02 | 11.59 | 0.6431 | 1.06 | 6.86 | 649,078.00 | 17.13 | 14.47 | 19.38 | 17.18 | 70.13 | 69.77 | 26.64 | 25.77 | 2.27 | 18.96 | 0.5567 | 26.89 | 5.74 | 7.96 | 10.88 | 11.13 | 16.71 | 24.37 |
Data as of Nov 21 2024. Currency figures normalised to Daiichi Sankyo Co Ltd's reporting currency: US Dollar USD
0.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Azimuth Capital Investment Management LLCas of 30 Sep 2024 | 314.92k | 0.02% |
| Arctic Asset Management AS (Sweden)as of 30 Sep 2024 | 177.08k | 0.01% |
| Madison Asset Management LLCas of 30 Sep 2024 | 76.22k | 0.00% |
| Ramirez Asset Management, Inc.as of 30 Sep 2024 | 69.67k | 0.00% |
| Causeway Capital Management LLCas of 07 Nov 2024 | 56.26k | 0.00% |
| Nia Impact Advisors LLCas of 31 Aug 2024 | 36.21k | 0.00% |
| Yousif Capital Management LLCas of 30 Sep 2024 | 29.89k | 0.00% |
| RhumbLine Advisers LPas of 30 Sep 2024 | 27.90k | 0.00% |
| Canopy Partners LLCas of 30 Sep 2024 | 6.67k | 0.00% |
| ShariaPortfolio, Inc.as of 07 Nov 2024 | 3.92k | 0.00% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
